Member Info for Wisheyedbortum

Many thanks researcher1. It would appear that there are some pretty impressive companies around at present that are on the verge of making some serious money over the next 2-3 years. Avacta is another one and probably Versarien, but the wait is a real tease. I will probably dip the toe in Angle shortly as I am finding the "eggs in one basket" situation too limiting. GL.

Thanks Seeingtom. I think that AGL could well be on the brink, but I will have to look further into revenues.GL.

I have been following AGL since it was 3p but have never understood where the revenue stream will come from. Is it sales of the parsortix equipment or as a service, would someone mind explaining please.

Just bought a few of these. Interesting looking company.

Nothing new there really except for the part about working with two of the worlds biggest biotech companies. I keep a reasonable holding of AVCT and expect to trade it on news, but I'll reinvest big time towards the end of 2020 when human trials begin. Still a very exciting company.

Why aren't all shares like WEY. Buy on Tuesday and I'm up a grand by Friday.

Good to see directors buying.

According to Investors Chronicle, the Aecom announcement is delayed, But (according to an NR tweet) It's not the fault of the customer or their customer. In fact the IC article is generally pretty disparaging towards VRS.

DD, the major problem you have is indecision. I didn't want to buy Fevertree on a £3.00 spike and then again at £7.00 after that it was out of my pricerange. It's now at £31.00. The same happened with Blue Prism. At some point, you just have to trust your own research and go for it. I first bought at 220p then at 228p and topped up at 312p, so you can imagine after the last couple of days I would be panicking, but no, I shut down my pc and went out to mix some cement. At some point you have to make a decision and live by it, win or lose.

I'm slightly out of my depth here so I would have a word with HL about whether it is more cost effective for you to sell your shares and move cash over because as I remember, HL will sell all your shares and re-buy them in your new HL accounts anyway. If you will be charged an exit fee for each share you hold in your old accounts, if you no longer hold any shares they can't charge you an exit fee unless they charge a levy on moving cash. These are just my thoughts which may be rubbish, but do talk to HL first before doing anything. They are very helpful, and good luck.

It's a long time since I transferred to Hargreaves Lansdown, but I have found them to be top notch and with reasonable prices, although not the cheapest their, service is brilliant. It's up to you, but trading costs are about £11 per trade if you do it yourself. I would move cash rather than shares if I were you and even though HL doesn't charge to transfer to them, their non diy share dealing charges are quite high. Wherever you go, set up a share dealing ISA and transfer cash into it. If you prefer a trading account and you have a trusted partner (wife etc) put it in joint names because it doubles your CGT allowance. I'm pretty sure this is correct.

"Real Long Termers" Is this some kind of badge of honour? It strikes me that you just got your timing badly wrong. I invested just over a year ago and I'm over 200% up, so do I qualify for good luck or did I just get my timing right?

.....you are interested, I am heavily into VRS which has massive potential and has made terrific profits for me so far and also Avacta (AVCT) which also has huge potential when the in vivo trials start in 2020. I also missed Fevertree and Blue Prism, but hopefully just in time with RENE.

...some more today.

Yes Manifesto, I have been following Avacta since 2009 and It's only just making headway this year, but the next few years could be transformational for the company and the antibody business. I was in RENE when the sp was hyped up to 5p for a placing, but drifted back to 3p,so I got out. Looking forward to seeing where this goes. GL.

I quite agree and there's also the "too late to get in at a good price" syndrome. I made that mistake with Blue Prism and Fevertree. I bought in here at £2.20 which is very unusual for me, but I am beginning to think that it will be money well invested even though I've only bought 1500 shares.

Sounds like the bloke from Grapheneca has found one of NRs scripts and is reading it word for word. I just hope that VRS doesn't have to fight IP lawsuites.

...to extend trials of graphene enhanced road surface as it appears to have increased durability by 250%. Reported on Proactive Investors.

What caught my eye with AGM was the drop from £2.85 to 35p. A similar path to HAYD.

Signed yesterday.